Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560082 | 0.79 | HTR7 (0.73) | HTR7HTR1AHTR2AHTR5AHTR6 | |
| SCHEMBL28041973 | 0.78 | ADRB1 (0.61) | MAPTLMNAMAPK1KMT2AALDH1A1 | |
| SCHEMBL19640677 | 0.77 | PDCD1 (0.49) | MAPTHTR7HTR1AHTR2AHTR5A | |
| SCHEMBL21855628 | 0.76 | RECQL (0.50) | HTR1AHTR2AALDH1A1 | |
| SCHEMBL20294480 | 0.76 | MAPT (0.41) | MAPTHTR7HTR1AHTR2AHTR5A | |
| SCHEMBL15238575 | 0.75 | MEN1 (0.47) | MAPTLMNAKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL30477888 | 0.75 | PDCD1 (0.55) | MAPTHTR7HTR1AHTR2AHTR5A | |
| SCHEMBL19640613 | 0.75 | PDCD1 (0.55) | MAPTHTR7HTR1AHTR2AHTR5A | |
| SCHEMBL1361268 | 0.74 | ADRB1 (0.58) | MAPTHTR7LMNAMGLLKMT2A | |
| SCHEMBL20294433 | 0.74 | PDCD1 (0.49) | MAPTHTR7HTR1AHTR2AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| EP-3464279-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4685/4885HTR7 3319/4885HTR1A 2910/4885 |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPT 4685/4885HTR7 3319/4885HTR1A 2910/4885 |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4685/4885HTR7 3319/4885HTR1A 2910/4885 |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | MAPT 4685/4885HTR7 3319/4885HTR1A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.